BACKGROUND: Osteosarcoma is the most common malignant bone tumor in children. Despite the advent of chemotherapy, the survival of osteosarcoma patients has not been significantly improved recently. Chemokines are a group of signaling molecules that have been implicated in tumorigenesis and metastasis. METHODS: The authors used an antibody microarray to identify chemokines that were elevated in the plasma samples of osteosarcoma patients. The results were validated using enzyme-linked immunosorbent assays on an independent set of samples. The tumor expressions of 3 chemokines were examined in 2 sets of osteosarcoma tissue arrays. The authors also evaluated the proliferative effect of the chemokines in 4 osteosarcoma cell lines. RESULTS: The authors found that the plasma levels of CXCL4, CXCL6, and CXCL12 in the osteosarcoma patients were significantly higher than those in the controls, and the results were validated by an independent osteosarcoma cohort (P < .05). However, CXCL4 (100%) and CXCL6 (91%) were frequently expressed in osteosarcoma, whereas CXCL12 was only expressed in 4%. Survival analysis further showed that higher circulating levels of CXCL4 and CXCL6, but not CXCL12, were associated with a poorer outcome of osteosarcoma patients. Addition of exogenous chemokines significantly promoted the growth of different osteosarcoma cells (P < .05). CONCLUSIONS: The results demonstrate that CXCL4 and CXCL6 are frequently expressed in osteosarcoma, and that the plasma levels of these 2 chemokines are associated with patient outcomes. Further study of these circulating chemokines may provide a promising approach for prognostication of osteosarcoma. Targeting these chemokines or their receptors may also lead to a novel therapeutic invention.
BACKGROUND:Osteosarcoma is the most common malignant bone tumor in children. Despite the advent of chemotherapy, the survival of osteosarcomapatients has not been significantly improved recently. Chemokines are a group of signaling molecules that have been implicated in tumorigenesis and metastasis. METHODS: The authors used an antibody microarray to identify chemokines that were elevated in the plasma samples of osteosarcomapatients. The results were validated using enzyme-linked immunosorbent assays on an independent set of samples. The tumor expressions of 3 chemokines were examined in 2 sets of osteosarcoma tissue arrays. The authors also evaluated the proliferative effect of the chemokines in 4 osteosarcoma cell lines. RESULTS: The authors found that the plasma levels of CXCL4, CXCL6, and CXCL12 in the osteosarcomapatients were significantly higher than those in the controls, and the results were validated by an independent osteosarcoma cohort (P < .05). However, CXCL4 (100%) and CXCL6 (91%) were frequently expressed in osteosarcoma, whereas CXCL12 was only expressed in 4%. Survival analysis further showed that higher circulating levels of CXCL4 and CXCL6, but not CXCL12, were associated with a poorer outcome of osteosarcomapatients. Addition of exogenous chemokines significantly promoted the growth of different osteosarcoma cells (P < .05). CONCLUSIONS: The results demonstrate that CXCL4 and CXCL6 are frequently expressed in osteosarcoma, and that the plasma levels of these 2 chemokines are associated with patient outcomes. Further study of these circulating chemokines may provide a promising approach for prognostication of osteosarcoma. Targeting these chemokines or their receptors may also lead to a novel therapeutic invention.
Authors: Yan Lavrovsky; Yan A Ivanenkov; Konstantin V Balakin; Darya A Medvedeva; Alexandre V Ivachtchenko Journal: Mini Rev Med Chem Date: 2008-10 Impact factor: 3.862
Authors: J M Birch; R D Alston; R J McNally; D G Evans; A M Kelsey; M Harris; O B Eden; J M Varley Journal: Oncogene Date: 2001-08-02 Impact factor: 9.867
Authors: E Van Coillie; I Van Aelst; A Wuyts; R Vercauteren; R Devos; C De Wolf-Peeters; J Van Damme; G Opdenakker Journal: Am J Pathol Date: 2001-10 Impact factor: 4.307
Authors: Su Young Kim; Chih Hung Lee; Brieanne V Midura; Choh Yeung; Arnulfo Mendoza; Sung Hyeok Hong; Ling Ren; Donald Wong; Walter Korz; Ahmed Merzouk; Hassan Salari; Hong Zhang; Sam T Hwang; Chand Khanna; Lee J Helman Journal: Clin Exp Metastasis Date: 2007-12-11 Impact factor: 5.150
Authors: P Di Roberto; P Benedetti Panici; G Scambia; F Laghi; P A Margariti; S Mancuso; A Bompiani Journal: Eur J Gynaecol Oncol Date: 1986 Impact factor: 0.196
Authors: Ricardo J Flores; Aaron J Kelly; Yiting Li; Xiang Chen; Colin McGee; Mark Krailo; Donald A Barkauskas; John Hicks; Tsz-Kwong Man Journal: Pediatr Blood Cancer Date: 2017-05-24 Impact factor: 3.167
Authors: Ricardo J Flores; Aaron J Kelly; Yiting Li; Manjula Nakka; Donald A Barkauskas; Mark Krailo; Lisa L Wang; Laszlo Perlaky; Ching C Lau; M John Hicks; Tsz-Kwong Man Journal: Cancer Date: 2016-08-16 Impact factor: 6.860
Authors: Eric S Schafer; Rachel E Rau; Stacey L Berg; Xiaowei Liu; Charles G Minard; Alexander J R Bishop; J Carolina Romero; M John Hicks; Marvin D Nelson; Stephan Voss; Joel M Reid; Elizabeth Fox; Brenda J Weigel; Susan M Blaney Journal: Pediatr Blood Cancer Date: 2019-11-14 Impact factor: 3.838
Authors: Jiang Jian; Yanli Pang; H Hannah Yan; Yongfen Min; Bhagelu R Achyut; M Christine Hollander; P Charles Lin; Xinhua Liang; Li Yang Journal: Oncotarget Date: 2017-04-25
Authors: Francesco R Evola; Luciano Costarella; Vito Pavone; Giuseppe Caff; Luca Cannavò; Andrea Sessa; Sergio Avondo; Giuseppe Sessa Journal: Front Pharmacol Date: 2017-04-07 Impact factor: 5.810
Authors: Thomas Gp Grünewald; Marta Alonso; Sofia Avnet; Ana Banito; Stefan Burdach; Florencia Cidre-Aranaz; Gemma Di Pompo; Martin Distel; Heathcliff Dorado-Garcia; Javier Garcia-Castro; Laura González-González; Agamemnon E Grigoriadis; Merve Kasan; Christian Koelsche; Manuela Krumbholz; Fernando Lecanda; Silvia Lemma; Dario L Longo; Claudia Madrigal-Esquivel; Álvaro Morales-Molina; Julian Musa; Shunya Ohmura; Benjamin Ory; Miguel Pereira-Silva; Francesca Perut; Rene Rodriguez; Carolin Seeling; Nada Al Shaaili; Shabnam Shaabani; Kristina Shiavone; Snehadri Sinha; Eleni M Tomazou; Marcel Trautmann; Maria Vela; Yvonne Mh Versleijen-Jonkers; Julia Visgauss; Marta Zalacain; Sebastian J Schober; Andrej Lissat; William R English; Nicola Baldini; Dominique Heymann Journal: EMBO Mol Med Date: 2020-10-13 Impact factor: 12.137
Authors: Yulia A Savitskaya; Genaro Rico-Martínez; Luis Miguel Linares-González; Ernesto Andrés Delgado-Cedillo; René Téllez-Gastelum; Alfonso Benito Alfaro-Rodríguez; Antonio Redón-Tavera; José Clemente Ibarra-Ponce de León Journal: Clin Sarcoma Res Date: 2012-03-23